Khairullina V, Martynova Y
Molecules. 2023; 28(23).
PMID: 38067446
PMC: 10708366.
DOI: 10.3390/molecules28237715.
Sokouti B, Hamzeh-Mivehroud M
BMC Chem. 2023; 17(1):63.
PMID: 37349775
PMC: 10286388.
DOI: 10.1186/s13065-023-00970-x.
Hu L, Li Z, Tang Z, Zhao C, Zhou X, Hu P
BMC Bioinformatics. 2022; 23(1):447.
PMID: 36303135
PMC: 9608884.
DOI: 10.1186/s12859-022-04999-y.
Okafor S, Angsantikul P, Ahmed H
Int J Mol Sci. 2022; 23(20).
PMID: 36293006
PMC: 9603388.
DOI: 10.3390/ijms232012149.
Kaur R, Sharma P, Gupta G, Ntie-Kang F, Kumar D
Molecules. 2020; 25(9).
PMID: 32365518
PMC: 7249135.
DOI: 10.3390/molecules25092070.
Dominant Negative MA-CA Fusion Protein Is Incorporated into HIV-1 Cores and Inhibits Nuclear Entry of Viral Preintegration Complexes.
Anderson-Daniels J, Singh P, Sowd G, Li W, Engelman A, Aiken C
J Virol. 2019; 93(21).
PMID: 31413124
PMC: 6803256.
DOI: 10.1128/JVI.01118-19.
An Efficient Synthesis of Hydroxyethylene Dipeptide Isosteres: The Core Unit of Potent HIV-1 Protease Inhibitors.
Ghosh A, McKee S, Thompson W
J Org Chem. 2018; 56(23):6500-6503.
PMID: 30393394
PMC: 6214462.
DOI: 10.1021/jo00023a009.
Effects of Amprenavir on HIV-1 Maturation, Production and Infectivity Following Drug Withdrawal in Chronically-Infected Monocytes/Macrophages.
Borrajo A, Ranazzi A, Pollicita M, Bruno R, Modesti A, Alteri C
Viruses. 2017; 9(10).
PMID: 28956865
PMC: 5691629.
DOI: 10.3390/v9100277.
A Novel Class of HIV-1 Antiviral Agents Targeting HIV via a SUMOylation-Dependent Mechanism.
Madu I, Li S, Li B, Li H, Chang T, Li Y
Sci Rep. 2015; 5:17808.
PMID: 26643614
PMC: 4672295.
DOI: 10.1038/srep17808.
Eradication of HIV-1 from the macrophage reservoir: an uncertain goal?.
Abbas W, Tariq M, Iqbal M, Kumar A, Herbein G
Viruses. 2015; 7(4):1578-98.
PMID: 25835530
PMC: 4411666.
DOI: 10.3390/v7041578.
High-affinity RNA Aptamers Against the HIV-1 Protease Inhibit Both In Vitro Protease Activity and Late Events of Viral Replication.
Duclair S, Gautam A, Ellington A, Prasad V
Mol Ther Nucleic Acids. 2015; 4:e228.
PMID: 25689224
PMC: 4345311.
DOI: 10.1038/mtna.2015.1.
Type I interferon rapidly restricts infectious hepatitis C virus particle genesis.
Meredith L, Farquhar M, Tarr A, McKeating J
Hepatology. 2014; 60(6):1891-901.
PMID: 25066844
PMC: 4265257.
DOI: 10.1002/hep.27333.
Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance.
Rabi S, Laird G, Durand C, Laskey S, Shan L, Bailey J
J Clin Invest. 2013; 123(9):3848-60.
PMID: 23979165
PMC: 4381280.
DOI: 10.1172/JCI67399.
Drug discovery prospect from untapped species: indications from approved natural product drugs.
Zhu F, Ma X, Qin C, Tao L, Liu X, Shi Z
PLoS One. 2012; 7(7):e39782.
PMID: 22808057
PMC: 3394748.
DOI: 10.1371/journal.pone.0039782.
Characterization of the human endogenous retrovirus K Gag protein: identification of protease cleavage sites.
Kraus B, Boller K, Reuter A, Schnierle B
Retrovirology. 2011; 8:21.
PMID: 21429186
PMC: 3073897.
DOI: 10.1186/1742-4690-8-21.
Potent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein-ligand X-ray studies.
Ghosh A, Gemma S, Takayama J, Baldridge A, Leshchenko-Yashchuk S, Miller H
Org Biomol Chem. 2008; 6(20):3703-13.
PMID: 18843400
PMC: 2797486.
DOI: 10.1039/b809178a.
Atomistic simulations of the HIV-1 protease folding inhibition.
Verkhivker G, Tiana G, Camilloni C, Provasi D, Broglia R
Biophys J. 2008; 95(2):550-62.
PMID: 18375506
PMC: 2440460.
DOI: 10.1529/biophysj.107.127621.
Targeting structural flexibility in HIV-1 protease inhibitor binding.
Hornak V, Simmerling C
Drug Discov Today. 2007; 12(3-4):132-8.
PMID: 17275733
PMC: 4767006.
DOI: 10.1016/j.drudis.2006.12.011.
A human immunodeficiency virus type 1 protease biosensor assay using bioluminescence resonance energy transfer.
Hu K, Clement J, Abrahamyan L, Strebel K, Bouvier M, Kleiman L
J Virol Methods. 2005; 128(1-2):93-103.
PMID: 15951029
PMC: 7112859.
DOI: 10.1016/j.jviromet.2005.04.012.
Coupling of human immunodeficiency virus type 1 fusion to virion maturation: a novel role of the gp41 cytoplasmic tail.
Wyma D, Jiang J, Shi J, Zhou J, Lineberger J, Miller M
J Virol. 2004; 78(7):3429-35.
PMID: 15016865
PMC: 371074.
DOI: 10.1128/jvi.78.7.3429-3435.2004.